ArticleTuberculosis (Edinburgh, Scotland)2020
Efficient genome editing in pathogenic mycobacteria using Streptococcus thermophilus CRISPR1-Cas9.
Article in Tuberculosis (Edinburgh, Scotland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Multiple aspartic proteases process PE and PPE proteins on the mycobacterial surface of pathogenic mycobacteria.The Journal of biological chemistry · 2026Article
- AscF in the mycobacterial CIII-CIV supercomplex lacks metal and nucleotide binding but links malate oxidation to respiration.FEBS letters · 2026Article
- Article
- A new role for lipoproteins LpqZ and FecB in orchestrating mycobacterial cell envelope biogenesis.mBio · 2026Article
- Mycobacteriophage Mcgavigan Uses Noncanonical Bxb1-Like Repressor for Heterotypic Superinfection Immunity.Journal of basic microbiology · 2026Article
- Advances and Challenges in Mycobacterial Genetic Engineering: Techniques for Knockout, Knockdown and Overexpression.Journal of microbiology and biotechnology · 2025Review
- The mevalonate pathway of isoprenoid biosynthesis supports metabolic flexibility inJournal of bacteriology · 2025Article
- PPE51 modulates membrane integrity inmBio · 2025Article
- STAGE: A compact and versatile TnpB-based genome editing toolkit forProceedings of the National Academy of Sciences of the United States of America · 2025Article
- Genome-wide phenotypic insights into mycobacterial virulence using Drosophila melanogaster.PLoS pathogens · 2025Article
- An unusual genetic switch controlsbioRxiv : the preprint server for biology · 2025Article
- The mevalonate pathway of isoprenoid biosynthesis supports metabolic flexibility inbioRxiv : the preprint server for biology · 2025Article
- Fluorescence-based CRISPR interference system for controlled genetic repression and live single-cell imaging in mycobacteria.FEBS letters · 2025Article
- A CRISPR/Cas9-based system using dual-sgRNAs for efficient gene deletion inFrontiers in microbiology · 2025Article
- Review
- CRISPR technology in human diseases.MedComm · 2024Review
- Modulating mycobacterial envelope integrity for antibiotic synergy with benzothiazoles.Life science alliance · 2024Article
- CRISPR/Cas9 gene editing: a novel strategy for fighting drug resistance in respiratory disorders.Cell communication and signaling : CCS · 2024Review
- Vitamin BMicrobiology spectrum · 2024Article
- Blunted blades: new CRISPR-derived technologies to dissect microbial multi-drug resistance and biofilm formation.mSphere · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The ability to genetically engineer pathogenic mycobacteria has increased significantly over the last decades due to the generation of new molecular tools. Recently, the application of the Streptococcus pyogenes and the Streptococcus thermophilus CRISPR-Cas9 systems in mycobacteria has enabled gene editing and efficient CRISPR interference-mediated transcriptional regulation. Here, we converted CRISPR interference into an efficient genome editing tool for mycobacteria. We demonstrate that the Streptococcus thermophilus CRISPR1-Cas9 (Sth1Cas9) is functional in Mycobacterium marinum and Mycobacterium tuberculosis, enabling highly efficient and precise DNA breaks and indel formation, without any off-target effects. In addition, with dual sgRNAs this system can be used to generate two indels simultaneously or to create specific deletions. The ability to use the power of the CRISPR-Cas9-mediated gene editing toolbox in M. tuberculosis with a single step will accelerate research into this deadly pathogen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.